dolasetron

Trade name: anzemet

Small moleculeapproved

Approved

Sep 11, 1997

Dolasetron is an antinauseant and antiemetic agent, which is approved as a mesylate salt under the brand name anzement for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses; and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. The serotonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine, and that the released serotonin then activates 5-HT3 receptors located on vagal efferents to initiate the vomiting reflex. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. Dolasetron mesilate is rapidly reduced by carbonyl reductase to form its major pharmacologically active metabolite reduced dolasetron. In addition dolasetron was in the phase III clinical trials for the investigation, that intravenous using of dolasetron mesilate reduces pain intensity in patients with fibromyalgia. — NCATS

Clinical trial activity

11 trials · 13 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 1999 (NCT00003817)

Timeline

1990s

Sep 11, 1997
Validus Pharmaceuticals — Earliest FDA Approval
Sep 11, 1997
Validus Pharmaceuticals — NDA Organization
Sep 11, 1997
Validus Pharmaceuticals — Marketing Organization
Sep 11, 1997
Validus Pharmaceuticals — NDA Secondary Org
Jan 1, 1999
Earliest Phase 2 Sponsor(trial)

2000s

Jan 1, 2001
Earliest Phase 3 Sponsor(trial)

2010s

Jan 1, 2016
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Serotonin 3a (5-HT3a) receptorANTAGONIST
HTR3A antagonist
Selective
- 5-hydroxytryptamine receptor 3A (HTR3A) ↗

Approval history

approvedSep 11, 1997

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12

Mol. weight: 324.38 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral, Parenteral
Availability: Discontinued

Oral

Yes

Parenteral

Yes

Topical

Sources

Also known as

1h-indole-3-carboxylic acid, (6r,9as)-octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl ester, rel-, methanesulfonate, hydrate (1:1:1)
1h-indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl ester, (2-alpha,6-alpha,8-alpha,9a-beta)-
1h-indole-3-carboxylic acid-trans-octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl ester methanesulfonate
anemet
anzemet
anzemet
anzemet
anzemet
anzemet
anzemet hydrate
azasetron
azasetron
azasetron hcl
azasetron hydrochloride
azasetron hydrochloride
azasetron hydrochloride
azasetron hydrochloride
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasetron
dolasétron
dolasétron
dolasetron mesilate
dolasetron mesilate
dolasetron mesilate
dolasetron mesilate monohydrate
dolasetron mesylate
dolasetron mesylate
dolasetron mesylate
dolasetron mesylate
dolasetron mesylate
dolasetron mesylate
dolasetron mesylate hydrate
dolasetron mesylate monohydrate
dolasetron methanesulfonate hydrate
dolasetronum
dolasetronum
indole-3-carboxylic acid, ester with (8r)-hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one
mdl 73147ef
mdl 73,147ef
mdl 73,147ef
mdl 73,147ef
mdl 73,147ef
mdl 73,147ef
mdl 73,147ef
mdl-73147ef
mdl-73147ef
mdl-73147ef
nazasetron
octahydro-3-oxo-2,6-methano-2h-quinolizin-8-yl 1h-indole-3-carboxylate
sens-401

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05628233	Phase 2	Dec 31, 2022	Sensorion
NCT05258773	Phase 2	Aug 10, 2022	Sensorion, University of Melbourne
NCT04817189	Phase 4	Feb 1, 2021	Helsinn, The Hong Kong Polytechnic University
NCT03603314	Phase 2/Phase 3 (Phase 3)	Oct 31, 2018	Sensorion
NCT03071003	Phase 1	Oct 27, 2016	Sensorion, Simbec-Orion
NCT02625181	N/A	Jul 1, 2016	University of Washington, Vanderbilt University
NCT01636947	Phase 4	Dec 12, 2012	Merck
NCT02550119	N/A	Apr 19, 2006	National Cancer Institute (NCI), University of Southern California
NCT00820326	Phase 3	Mar 1, 2004	University of Limoges
NCT00020657	Phase 3	Jul 1, 2001	National Cancer Institute (NCI), New York University, University of Rochester
NCT00003817	Phase 2	Oct 1, 1999	National Cancer Institute (NCI), New York University, University of Rochester

Showing 11 of 11 trials

Page 1 / 1

Organizations

Research & Development (13)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Sensorion	For profit	4	3	3	2016
National Cancer Institute (NCI)	Government	3	0	3	1999
New York University	Academic/Hospital	2	0	2	1999
University of Rochester	Academic/Hospital	2	2	2	1999
Helsinn	For profit	1	1	1	2021
Merck	For profit	1	1	1	2012
Simbec-Orion	For profit	1	1	1	2016
The Hong Kong Polytechnic University	Academic/Hospital	1	0	1	2021
University of Limoges	Academic/Hospital	1	1	1	2004
University of Melbourne	Academic/Hospital	1	0	1	2022
University of Southern California	Academic/Hospital	1	1	1	2006
University of Washington	Academic/Hospital	1	0	1	2016
Vanderbilt University	Academic/Hospital	1	1	1	2016

13 organizations

Page 1 / 1

Marketing (3)

Organization	Org type	Relationship	Date
Validus Pharmaceuticals	For profit	NDA	Sep 11, 1997
Validus Pharmaceuticals	For profit	MKTG	Sep 11, 1997
Validus Pharmaceuticals	For profit	NDA2	Sep 11, 1997